logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Journal Article
|Research

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)

Burza S, Mahajan R, Singh A, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Mitra G, Kumar R, Verma N, Das P
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20-25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.

Countries

India

Subject Area

neglected tropical diseaseskala azarHIV/AIDS

Languages

English
DOI
10.1371/journal.pntd.0003053
Published Date
07 Aug 2014
Journal
PLOS Neglected Tropical Diseases
Volume | Issue | Pages
Volume 8, Issue 8, Pages e3053
Issue Date
2014-08-07
Dimensions Badge
Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome) | Journal Article / Research | MSF Science Portal